Overview
CNS disorders affect a vast patient population and represent a huge area of
unmet therapeutic need. In the United States alone, Alzheimers disease (AD),
Parkinsons disease (PD), and amyotrophic lateral sclerosis (ALS) afflict more
than 6.5 million people. Drug discovery efforts for the most prevalent CNS
diseases have met with varying success; it is estimated that billions of dollars
are spent every year on prescription drug sales, however, many current therapies
merely treat the symptoms but do not provide cures.
The complexity of CNS diseases make this area a challenging but potentially
very rewarding area for research. Neurogenomics and Neurotherapeutic Strategies:
New Directions in Platforms, Targets, and Therapeutic Approaches evaluates drug
development efforts in six major CNS diseases:
- Alzheimers disease
-
Parkinsons disease
-
Amyotrophic Lateral Sclerosis
-
Schizophrenia
-
Depression
Bipolar disorder
This report surveys the numerous R&D efforts under way at companies and
institutions around the world, focusing on discovery projects, preclinical
studies, and early-stage human trials. It also addresses investigational
methods, proposed mechanisms of action, pathways, and targets that research
teams are exploring in order to move one step closer to developing effective
therapeutics. Novel tools and platforms, including animal models, molecular
imaging, and biomarkers, will also be covered.
View Cart
